Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

CinCor Pharma Shares Trade Higher After Positive Data From Hypertension Drug

Published 08/08/2022, 15:11
Updated 08/08/2022, 16:11
© Reuters.  CinCor Pharma Shares Trade Higher After Positive Data From Hypertension Drug
CINC
-

  • CinCor Pharma Inc (NASDAQ: CINC) has announced topline results from Phase 2 BrigHtn trial evaluating baxdrostat for treatment-resistant hypertension.
  • Results showed baxdrostat met its primary endpoint and achieved a statistically significant placebo-adjusted reduction in systolic blood pressure (SBP), including 11 mmHg at 2 mg.
  • BrigHtn successfully met its primary endpoint, demonstrating a statistically significant change from baseline in mean seated SBP versus placebo for the 2 mg and 1 mg doses:
  • Secondary endpoint results included baxdrostat significantly lowering diastolic blood pressure (DBP) by 5.2 mmHg in the 2mg dose, and approximately 46% of patients in the 2 mg dose arm achieving blood pressure control.
  • No drug-related serious adverse events were observed, or major safety concerns were reported across all three dose cohorts.
  • One subject experienced an isolated instance of elevated potassium, deemed drug-related. However, upon retesting, the potassium level for this patient dropped sufficiently to allow resumption of baxdrostat.
  • In July, CinCor completed enrollment in the Phase 2 HALO trial with 249 patients. HALO is studying the efficacy and safety of baxdrostat in patients whose blood pressure is not controlled despite treatment with up to two antihypertensive agents and remains on track to be completed in 2H of 2022.
  • Price Action: CINC shares are up 68% at $39.39 on the last check Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.